The TuBerculosis Vaccine Initiative (TBVI) is a non-profit foundation that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people. As a Product Development Partnership (PDP), TBVI integrates, translates and prioritises R&D efforts to discover and develop new TB vaccines and biomarkers for global use. TBVI provides essential services that support the R&D efforts of its consortium partners – 50 partners from academia, research institutes and private industry in the TB vaccine field. These services include:
- project identification, design and development;
- project management;
- resource mobilisation;
- knowledge development, exchange and networking;
- technical advice and support for product and clinical development.
TBVI does not have its own commercial interests. Ownership of vaccine candidates and biomarkers, and any intellectual property rights remain with researchers and vaccine developers. Access and affordability of TB vaccines for the developing world is a statutory objective of TBVI and is a commitment that is part of each project grant agreement supported by TBVI.
TBVI innovates and diversifies the pipeline for TB vaccines. It accelerates the most promising vaccine and biomarker candidates through the pipeline, applying portfolio management to support decision-making in an objective and transparent manner and to use the available financial resources effectively. It seeks to align its portfolio management approach with other global efforts, in particular with the portfolio management approach foreseen by the Global TB Vaccine Partnership (GTBVP).
New vaccines are urgently needed to stop tuberculosis. Every year almost 9 million new cases of this infectious disease are recorded. Every year around 1.5 million people die of TB, equaling one death every 22 seconds.
Company Details
- Employees
- 13
- Founded
- -
- Address
- Runderweg 6, 8219 Pk Lelystad,netherlands
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- tbvi.eu
- HQ
- 8219 PK Lelystad
- Competitors
- Tuberculosis Working Group - Research Center for Care and Control of Infectious Diseases UNPAD, National Institute of Tuberculosis and Respiratory Diseases (NITRD), South African Tuberculosis Vaccine Initiative (SATVI), Vaccine and Infectious Disease Organization (VIDO), VAC4EU - Vaccine Monitoring Collaboration for Europe, European Vaccine Initiative (EVI), MycobacteriumXL, Stop TB Partnership Working Group on New TB Vaccines, International Union Against Tuberculosis and Lung Disease (The Union), European Health and Digital Executive Agency (HaDEA).
Tuberculosis Vaccine Initiative (Tbvi) Questions
Tuberculosis Vaccine Initiative (Tbvi)'s website is tbvi.eu
Tuberculosis Vaccine Initiative (Tbvi)'s LinkedIn profile is https://nl.linkedin.com/company/tuberculosis-vaccine-inititive-tbvi-
Tuberculosis Vaccine Initiative (Tbvi) has
13 employees.
View email and phone details for 13
employees at Tuberculosis Vaccine Initiative (Tbvi).
Tuberculosis Vaccine Initiative (Tbvi)'s industry is
Research Services
Tuberculosis Vaccine Initiative (Tbvi)'s top competitors are
Tuberculosis Working Group - Research Center For Care And Control Of Infectious Diseases Unpad,
National Institute Of Tuberculosis And Respiratory Diseases (Nitrd),
South African Tuberculosis Vaccine Initiative (Satvi),
Vaccine And Infectious Disease Organization (Vido),
Vac4eu - Vaccine Monitoring Collaboration For Europe,
European Vaccine Initiative (Evi),
Mycobacteriumxl,
Stop Tb Partnership Working Group On New Tb Vaccines,
International Union Against Tuberculosis And Lung Disease (The Union),
European Health And Digital Executive Agency (Hadea).
Tuberculosis Vaccine Initiative (Tbvi)'s categories are Research Services
Tuberculosis Vaccine Initiative (Tbvi)'s founding year is 2008
